Author

P. E. Sanderson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:proteomics· 1 Research Focus:variant effect prediction· 1

Frequent Co-Authors

A. Simeonov· 2 shared J. H. Shrimp· 2 shared M. D. Hall· 2 shared M. Shen· 2 shared S. C. Kales· 2 shared C. Klumpp-Thomas· 1 shared C. Z. Chen· 1 shared H. Guo· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

A. Simeonov

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BiochemistrybioRxivFeb 4, 2022

A Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19

J. H. Shrimp, J. Janiszewski, C. Z. Chen…·M. D. Hall

The paper develops and validates a series of assays to identify TMPRSS2 inhibitors as potential COVID-19 treatments, identifying six compounds with varying clinical statuses.

DOI 10.1021/acsinfecdis.2c00172

proteomicsexperimental assay

𝕏 PostBluesky

BiochemistrybioRxivJun 23, 2020

An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19

J. H. Shrimp, S. C. Kales, P. E. Sanderson…·M. D. Hall

The paper describes an enzymatic TMPRSS2 assay for inhibitor discovery and profiling of FDA-approved therapeutics, showing varying potencies of tested compounds.

DOI 10.1021/acsptsci.0c00106

experimental assaydrug response / drug discovery

𝕏 PostBluesky